Nicotinic Acetylcholine Receptor alpha 5/CHRNA5 Antibody (268): sc-58606

AChRα5 Antibody (268) is a rat monoclonal IgG antibody that detects nicotinic acetylcholine receptor alpha 5 (AChRα5) in mouse, rat, human, and avian samples through applications such as western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). Anti-AChRα5 antibody (268) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates, providing versatility for different experimental needs. AChRα5, also known as LNCR2 or CHRNA5, is a critical component of the ligand-gated ion channel family, consisting of 468 amino acids and functioning as a multi-pass membrane protein. AChRα5 plays a vital role in mediating fast synaptic transmission by forming a transmembrane aqueous pore that allows ions to flow in response to acetylcholine binding at the postsynaptic membrane of the neuromuscular junction. The precise structure of AChRα5, which includes five homologous subunits, is essential for undergoing conformational changes upon neurotransmitter binding, thereby facilitating rapid communication between neurons and muscle cells. Understanding the structure and function of AChRα5 is crucial for elucidating its role in synaptic transmission and implications in various neurological disorders, making AChRα5 (268) monoclonal antibody an invaluable tool for researchers studying cholinergic signaling pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Nicotinic Acetylcholine Receptor alpha 5/CHRNA5 Antibody (268) References:

1. The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine addiction and lung cancer.  |  Improgo, MR., et al. 2010. Prog Neurobiol. 92: 212-26. PMID: 20685379
2. Contribution of Variants in CHRNA5/A3/B4 Gene Cluster on Chromosome 15 to Tobacco Smoking: From Genetic Association to Mechanism.  |  Wen, L., et al. 2016. Mol Neurobiol. 53: 472-484. PMID: 25471942
3. CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis.  |  Chen, LS., et al. 2015. J Natl Cancer Inst. 107: PMID: 25873736
4. Smoking Interacts With CHRNA5, a Nicotinic Acetylcholine Receptor Subunit Gene, to Influence the Risk of IBD-Related Surgery.  |  Cushing, KC., et al. 2018. Inflamm Bowel Dis. 24: 1057-1064. PMID: 29688464
5. Cholinergic Receptor Nicotinic Alpha 5 (CHRNA5) RNAi is associated with cell cycle inhibition, apoptosis, DNA damage response and drug sensitivity in breast cancer.  |  Cingir Koker, S., et al. 2018. PLoS One. 13: e0208982. PMID: 30543688
6. CHRNA5 rs16969968 polymorphism is associated with lung cancer risk: A meta-analysis.  |  Zhou, W., et al. 2020. Clin Respir J. 14: 505-513. PMID: 32049419
7. CHRNA5 belongs to the secondary estrogen signaling network exhibiting prognostic significance in breast cancer.  |  Shehwana, H., et al. 2021. Cell Oncol (Dordr). 44: 453-472. PMID: 33469842
8. CHRNA5 Is Overexpressed in Patients with Psoriasis and Promotes Psoriasis-Like Inflammation in Mouse Models.  |  Wang, J., et al. 2022. J Invest Dermatol. 142: 2978-2987.e6. PMID: 35513071
9. CHRNA5 links chandelier cells to severity of amyloid pathology in aging and Alzheimer's disease.  |  Rybnicek, J., et al. 2024. Transl Psychiatry. 14: 83. PMID: 38331937
10. Nicotine-induced CHRNA5 activation modulates CES1 expression, impacting head and neck squamous cell carcinoma recurrence and metastasis via MEK/ERK pathway.  |  Feng, C., et al. 2024. Cell Death Dis. 15: 785. PMID: 39472448

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Nicotinic Acetylcholine Receptor alpha 5/CHRNA5 Antibody (268) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-Nicotinic Acetylcholine Receptor alpha 5/CHRNA5 Antibody (268) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Nicotinic Acetylcholine Receptor alpha 5/CHRNA5 Antibody (268) Specifications

Alternate Product Name: AChRα5

Product Clone Name: 268

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target: AChRα5

Epitope Species: chicken

Product Reactivity/Detection: denatured neuronal nicotinic Acetylcholine Receptor α5

Species Reactivity/Detection: mouse, rat, human, avian

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, FCM

Vialing Information: Each vial contains 200 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for Nicotinic Acetylcholine Receptor alpha 5/CHRNA5 Antibody (268): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred Nicotinic Acetylcholine Receptor alpha 5/CHRNA5 antibody is Nicotinic Acetylcholine Receptor alpha 5/CHRNA5 Antibody (D-11): sc-376979.